-
Budesonide: From Inflammation to Lung Permeability
2026-08-30
Budesonide is an anti-inflammatory corticosteroid with value beyond conventional asthma inflammation models. This article explains how biomimetic chromatography and mass spectrometry can guide interpretation of pulmonary membrane behavior without confusing analytical permeability with biological efficacy.
-
GSK-923295: CENP-E Inhibitor Workflow Guide
2026-08-29
GSK-923295 provides a controlled chemical route to study CENP-E-dependent chromosome congression, mitotic arrest, and tumor-cell growth. This workflow guide connects biochemical potency with imaging, viability, centromere-architecture assays, and carefully interpreted colon cancer xenograft evidence.
-
Nanoplastics and MAPK/ERK Vascular Lipid Dysregulation
2026-08-28
A 2026 study shows that prenatal and lactational exposure to 100-nm polystyrene nanoplastics disrupts vascular lipid homeostasis in male mouse offspring and in MOVAS cells. The evidence supports a MAPK/ERK/UHRF1 pathway in this response, while also highlighting why developmental timing, sex, and pathway-specific controls are essential for interpreting nanoplastic cardiovascular toxicity.
-
Phagocytic Giant Cancer Macrophages in Blood
2026-08-28
The reference study presents circulating cancer-associated macrophage-like cells (CAMLs) as clinically informative polyploid giant cells rather than inert tumor debris. In a prospective, multi-institutional cohort, CAMLs correlated with disease progression and spread while displaying self-renewal, proangiogenic, and overlapping myeloid, epithelial, and endothelial features.
-
POx Lipids as PEG Alternatives in mRNA LNPs
2026-08-27
Holick and colleagues investigated poly(2-ethyl-2-oxazoline)-based lipids as substitutes for PEG-lipids in mRNA lipid nanoparticles. By varying polymer chain length and combining physicochemical, immunoreaction, transfection, and super-resolution microscopy analyses, the study identified a PEtOx-LNP formulation that outperformed the tested commercial PEG-lipid comparator in transfection-related measures.
-
MK-1775 Wee1 Kinase Inhibitor Workflows
2026-08-27
Build more informative MK-1775 experiments by pairing Wee1 pathway biomarkers with separate measures of growth inhibition and cell killing. This workflow guide covers checkpoint-abrogation assays, combination studies in p53-deficient models, dosing logic, and practical troubleshooting.
-
NBC19 Maps Lactate–NLRP3 Inflammation
2026-08-26
NBC19 is a potent NLRP3 inflammasome inhibitor for separating cytokine-processing events from lactate-driven macrophage signaling. This guide translates HMGB1 lactylation and exosomal release findings into a rigorous, hypothesis-led inflammation research workflow.
-
MOG (35-55): From EAE to Translation
2026-08-26
MOG (35-55) is more than an experimental autoimmune encephalomyelitis inducer: it is a controlled entry point for dissecting antigen-specific neuroinflammation, testing pathway hypotheses, and improving translational decisions in multiple sclerosis research. This article connects model design with the PARP7–STAT1/STAT2 axis and outlines how to use the peptide strategically without overstating what EAE can predict clinically.
-
FAK Inhibitor 14: A Mechanism-First Assay Guide
2026-08-25
FAK Inhibitor 14 provides a mechanism-first approach to studying focal adhesion kinase in cancer biology research. Learn how to connect target engagement, migration phenotypes, formulation, and cholesterol-adapted ovarian cancer models without overinterpreting a single assay.
-
DPP8/9 Inhibitors Activate CARD8 in Lymphocytes
2026-08-25
Johnson and colleagues show that resting human and rodent lymphocytes, particularly CD4+ and CD8+ T cells, can undergo CARD8-dependent pyroptosis after DPP8/9 inhibition. The study expands inflammasome biology beyond myeloid cells and identifies cellular activation state and species as important determinants of susceptibility.
-
Isochlorogenic acid A in Wound Repair Research
2026-08-24
Isochlorogenic acid A connects natural-product chemistry with antimicrobial, inflammation, and hydrogel wound-repair workflows. This guide translates a recent Fe3+-coassembled nanoparticle study into practical formulation, assay, and troubleshooting decisions while keeping solubility and evidence limitations visible.
-
AAL-993: VEGF Receptor Inhibitor Workflows
2026-08-24
AAL-993 is a selective VEGF receptor inhibitor for connecting kinase-level activity with endothelial, tumor angiogenesis, and melanoma models. This practical guide covers assay selection, dosing logic, reproducible workflows, and troubleshooting without overstating preclinical evidence.
-
Catalpol in Sepsis-Associated Encephalopathy
2026-08-23
The reference study shows that Catalpol improves LPS-induced cognitive impairment in mice through coordinated suppression of NF-κB-dependent neuroinflammation and enhancement of TrkB–BDNF signaling. Its value lies in combining behavioral, histological, pharmacokinetic, cellular, and target-engagement evidence to connect brain exposure with preservation of the blood-brain barrier and neuronal structure.
-
METTL16–SENP3–LTF Drives Ferroptosis Resistance
2026-08-22
Wang et al. identify an m6A-dependent METTL16–SENP3–LTF axis that protects hepatocellular carcinoma cells from iron-dependent lipid peroxidation and promotes tumor growth. The work connects RNA methylation, SUMO-related protein stability, and labile iron control, suggesting that disrupting this pathway could sensitize HCC to ferroptosis-inducing treatments.
-
GDC-0994 for ERK1/2 Pathway Research
2026-08-22
GDC-0994 is a potent, selective ERK1/2 inhibitor for connecting pathway biochemistry with cancer-cell and cholestatic liver models. This workflow translates ERK phosphorylation inhibition into practical viability, bile-flow, transporter-gene, and downstream p90RSK assays while emphasizing formulation and interpretation controls.